The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Maekawa, Tatsunori ^a   Mori, Sayuri ^a   Sasaki, Yui ^a   Miyajima, Takashi ^a   Azuma, Sadahiro ^b   Ohta, Etsuro ^a   Obata, Fumiya ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

LRRK2; Parkinsons disease; Transgenic mouse

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; OXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FETUS; GOLGI COMPLEX; LOCOMOTION; MICROTUBULE; MICROTUBULE ASSEMBLY; MOUSE; MUTATION; NEURITE; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NONHUMAN; OLFACTORY BULB; PARKINSON DISEASE; ROTAROD TEST; SUBSTANTIA NIGRA; TRANSGENIC MOUSE; VENTRAL TEGMENTUM;

ANIMALS; BEHAVIOR, ANIMAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HUMANS; LOCOMOTION; MICE; MICE, TRANSGENIC; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

MUS; MUS MUSCULUS;

EID: 84862230156     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-15     Document Type: Article

References (50)

1. A new locus for Parkinsons disease (PARK8) maps to chromosome 12p11.2- 290 q13.1. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F, Ann Neurol 2002 51 296 301 10.1002/ana.10113 11891824
2. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, Tsuji S, Obata F, Ann Neurol 2005 57 918 921 10.1002/ana.20484 15880653
3. Cloning of the gene containing mutations that cause PARK8-linked Parkinsons disease. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Burg M, Lopez De Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, De Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB, Neuron 2004 44 595 600 10.1016/j.neuron.2004.10.023 15541308
4. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoin S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T, Neuron 2004 44 601 607 10.1016/j.neuron.2004.11. 005 15541309
5. The RIP kinases: crucial integrators of cellular stress. Meylan E, Tschopp J, Trends Biochem Sci 2005 30 151 159 10.1016/j.tibs.2005.01.003 15752987
6. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Milosevic J, Schwarz SC, Ogunlade V, Meyer AK, Storch A, Schwarz J, Mol Neurodegener 2009 4 25 10.1186/1750-1326-4-25 19523245
7. LRRK2 in Parkinsons disease: function in cells and neurodegeneration. Webber PJ, West AB, FEBS J 2009 276 6436 6444 10.1111/j.1742-4658.2009.07342.x 19804415
8. LRRK2 function on actin and microtubule dynamics in Parkinson disease. Parisiadou L, Cai H, Commun Integr Biol 2010 3 396 400 10.4161/cib.3.5.12286 21057624
9. Diversity in the regulation of autophagy and mitophagy: lessons from Parkinsons disease. Chu CT, Parkinsons Dis 2011 789431
10. Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinsons disease. Li Y, Liu W, Oo F, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C, Nat Neurosci 2009 12 826 8 10.1038/nn.2349 19503083
11. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, Shen J, Proc Natl Acad Sci U S A 2009 106 34 14622 7 10.1073/pnas.0906334106 19667187
12. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z, J Neurosci 2009 30 1788 1797
13. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H, Neuron 2009 64 807 827 10.1016/j.neuron.2009.11.006 20064389
14. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Melrose HL, Dachsel JC, Behrouz B, Lincoln SJ, Yue M, Hinkle KM, Kent CB, Korvatska E, Taylor JP, Witten L, Liang YQ, Beevers JE, Boules M, Dugger BN, Serna VA, Gaukhman A, Yu X, Castanedes-Casey M, Braithwaite AT, Ogholikhan S, Yu N, Bass D, Tyndall G, Schellenberg GD, Dickson DW, Janus C, Farrer MJ, Neurobiol Dis 2010 40 503 517 10.1016/j.nbd.2010.07.010 20659558
15. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. Ramonet D, Daner JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ, PLoS One 2011 6 18568 10.1371/journal.pone.0018568 21494637
16. Temporal Expression of Mutant LRRK2 in Adult Rats Impairs Dopamine Reuptake. Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG, Int J Biol Sci 2011 7 753 761 21698001
17. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. Greggio E, Cookson MR, ASN Neuro 2009 1 00002 19570025
18. I(2020)T leucine-rich repeat kinase 2, the causative mutant molecule of familial Parkinson's disease, has a higher intracellular degradation rate than the wild-type molecule. Ohta E, Katayama Y, Kawakami F, Yamamoto M, Tajima K, Maekawa T, Iida N, Hattori S, Obata F, Biochem Biophys Res Commun 2009 390 710 715 10.1016/j.bbrc.2009.10.034 19833102
19. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B, EMBO J 2008 27 2432 2443 10.1038/emboj.2008.163 18701920
20. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Venderova K, Kabbach G, Abdel-Messih E, Zhang Y, Parks RJ, Imai Y, Gehrke S, Ngsee J, Lavoie MJ, Slack RS, Rao Y, Zhang Z, Lu B, Hague ME, Park DS, Hum Mol Genet 2009 18 4390 4404 10.1093/hmg/ddp394 19692353
21. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. Lee S, Liu HP, Lin WY, Guo H, Lu B, J Neurosci 2010 30 16959 16969 10.1523/JNEUROSCI.1807-10.2010 21159966
22. Role of microtubules in the organization of the Golgi complex. Thyberg J, Moskalewski S, Exp Cell Res 1999 246 263 279 10.1006/excr.1998.4326 9925741
23. Effects of MPTP on locomotor activity in mice. Colotla VA, Flores E, Oscos A, Meneses A, Tapia R, Neurotoxicol. Teratol 1990 12 405 407 10.1016/0892-0362(90)90061-G 2392101
24. The MPTP-treated mouse as a model of parkinsonism: How good is it? Heikkila RE, Sonsalla PK, Neurochem Int 1992 20 299 303 1304327
25. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D, Proc Natl Acad Sci U S A 2007 104 34 13804 13809 10.1073/pnas.0702753104 17702867
26. Somatostatin receptor 2 knockout/lacZ knockin mice show impaired motor coordination and reveal sites of somatostatin action within the striatum. Allen JP, Hathway GJ, Clarke NJ, Jowett MI, Topps S, Kendrick KM, Humphrey PP, Wilkinson LS, Emson PC, Eur J Neurosci 2003 17 1881 1895 10.1046/j.1460-9568. 2003.02629.x 12752788
27. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF, J Neurosci 2004 24 9434 9440 10.1523/JNEUROSCI.3080-04.2004 15496679
28. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. Allbutt HN, Henderson JM, J Neurosci Methods 2007 159 195 202 10.1016/j.jneumeth.2006.07.006 16942799
29. A rotarod test for evaluation of motor skill learning. Shiotsuki H, Yoshimi K, Shimo Y, Funayama M, Takamatsu Y, Ikeda K, Takahashi R, Kitazawa S, Hattori N, J Neurosci Methods 2010 189 180 185 10.1016/j.jneumeth.2010.03.026 20359499
30. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease. Ogura T, Ogata M, Akita H, Jitsuki S, Akiba L, Noda K, Hoka S, Saji M, Neurosci Res 2005 51 299 308 10.1016/j.neures.2004.12.006 15710494
31. Autosomal dominant familial Parkinson disease: older onset of age, and good response to levodopa therapy. Hasegawa K, Kowa H, Eur Neurol 1997 38 39 43 9276200
32. Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S, Parkinsonism Relat Disord 2009 15 300 306 10.1016/j.parkreldis.2008.07.010 18804399
33. Role of microtubules in the distribution of the Golgi apparatus: effect of taxol and microinjected anti-alpha-tubulin antibodies. Wehland J, Henkart M, Klausner R, Sandoval IV, Proc Natl Acad Sci U S A 1983 80 4286 4290 10.1073/pnas.80.14.4286 6136036
34. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR, Biochem J 2007 405 307 317 10.1042/BJ20070209 17447891
35. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL, Ann Neurol 2006 60 557 569 10.1002/ana.21019 17120249
36. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N, Curr Biol 2007 17 592 598 10.1016/j.cub.2007.01.074 17346966
37. Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-positive inclusions in patients with Parkinson's disease. Fujita Y, Ohama E, Takatama M, AI-Sarraj S, Okamoto K, Acta Neuropathol 2006 112 261 265 10.1007/s00401-006-0114-4 16855830
38. Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death. Gonatas NK, Stieber A, Gonatas JO, J Neurol Sci 2006 246 21 30 10.1016/j.jns.2006.01.019 16545397
39. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein. Lee HJ, Khoshaghideh F, Lee S, Lee SJ, Eur J Neurosci 2006 24 3153 3162 10.1111/j.1460-9568.2006.05210.x 17156376
40. Fragmentation of the Golgi apparatus: an early apoptotic event independent of the cytoskeleton. Mukherjee S, Chiu R, Leung SM, Shields D, Traffic 2007 8 369 378 10.1111/j.1600-0854.2007.00542.x 17394485
41. LRRK2 regulates synaptic vesicle endocytosis. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, Hatano T, Hattori N, Kim KS, Chang S, Seol W, Exp Cell Res 2008 314 2055 2065 10.1016/j.yexcr.2008. 02.015 18445495
42. LRRK2: A Problem Lurking in Vesicle Trafficking? Dihanich S, Manzoni C, J Neurosci 2011 31 9787 9788 10.1523/JNEUROSCI.1976-11.2011 21734269
43. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, De Astis S, Meixner A, Sarioglu H, Vogt-Weisenhorn DM, Wurst W, Gloeckner CJ, Matteoli M, Sala C, Ueffing M, J Neurosci 2011 31 2225 2237 10.1523/JNEUROSCI.3730-10.2011 21307259
44. LEE SJ: Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. Gosavi N, Lee HJ, Lee JS, Patel S, J Biol Chem 2002 277 48984 48992 10.1074/jbc.M208194200 12351643
45. Structural organization of the Golgi apparatus. Lowe M, Curr Opin Cell Biol 2011 23 85 93 10.1016/j.ceb.2010.10.004 21071196
46. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM, Hum Mol Genet 2007 16 223 232 17200152
47. Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis. Ohta E, Kubo M, Obata F, Biochem Biophys Res Commun 2010 391 242 7 10.1016/j.bbrc.2009.11.043 19912990
48. A comparative study of Lrrk2 function in primary neuronal cultures. Dachsel JC, Behrouz B, Yue M, Beevers JE, Melrose HL, Farrer MJ, Parkinsonism Relat Disord 2010 16 650 655 10.1016/j.parkreldis.2010.08.018 20850369
49. Microtubule assembly in the absence of added nucleotides. Shelanski ML, Gaskinn F, Cantor CR, Proc Natl Acad Sci U S A 1973 70 765 768 10.1073/pnas.70.3.765 4514990
50. Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation. Naoi M, Takahashi T, Nagatsu T, J Chromatogr 1988 427 229 238 2900841